These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23897494)

  • 1. Population pharmacodynamic modeling of exenatide after 2-week treatment in STZ/NA diabetic rats.
    Chen T; Kagan L; Mager DE
    J Pharm Sci; 2013 Oct; 102(10):3844-51. PubMed ID: 23897494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats.
    Li XG; Li L; Zhou X; Chen Y; Ren YP; Zhou TY; Lu W
    Acta Pharmacol Sin; 2012 Nov; 33(11):1379-86. PubMed ID: 22659626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing.
    Fineman M; Flanagan S; Taylor K; Aisporna M; Shen LZ; Mace KF; Walsh B; Diamant M; Cirincione B; Kothare P; Li WI; MacConell L
    Clin Pharmacokinet; 2011 Jan; 50(1):65-74. PubMed ID: 21142268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, in vitro and in vivo correlation, and efficacy of exenatide microspheres in diabetic rats.
    Li X; Zhao Z; Li L; Zhou T; Lu W
    Drug Deliv; 2015 Jan; 22(1):86-93. PubMed ID: 24467493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin/nicotinamide-induced diabetic mice.
    Gumuslu E; Cine N; Ertan M; Mutlu O; Komsuoglu Celikyurt I; Ulak G
    Fundam Clin Pharmacol; 2018 Apr; 32(2):174-180. PubMed ID: 29091313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Acting Phospholipid Gel of Exenatide for Long-Term Therapy of Type II Diabetes.
    Hu M; Zhang Y; Xiang N; Zhong Y; Gong T; Zhang ZR; Fu Y
    Pharm Res; 2016 Jun; 33(6):1318-26. PubMed ID: 26857900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration.
    Gedulin BR; Smith PA; Jodka CM; Chen K; Bhavsar S; Nielsen LL; Parkes DG; Young AA
    Int J Pharm; 2008 May; 356(1-2):231-8. PubMed ID: 18291606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological activity of AC3174, a peptide analog of exendin-4.
    Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
    Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Site-specific fatty chain-modified exenatide analogs with balanced glucoregulatory activity and prolonged in vivo activity.
    Sun L; Huang X; Han J; Cai X; Dai Y; Chu Y; Wang C; Huang W; Qian H
    Biochem Pharmacol; 2016 Jun; 110-111():80-91. PubMed ID: 27155328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes.
    Taylor K; Kim D; Nielsen LL; Aisporna M; Baron AD; Fineman MS
    Horm Metab Res; 2005 Oct; 37(10):627-32. PubMed ID: 16278786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans.
    Gao W; Jusko WJ
    Drug Metab Dispos; 2012 May; 40(5):990-7. PubMed ID: 22338110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The GLP-1 analogue exenatide improves hepatic and muscle insulin sensitivity in diabetic rats: tracer studies in the basal state and during hyperinsulinemic-euglycemic clamp.
    Wu H; Sui C; Xu H; Xia F; Zhai H; Zhang H; Weng P; Han B; Du S; Lu Y
    J Diabetes Res; 2014; 2014():524517. PubMed ID: 25580440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers.
    Shi S; Liu Y; Li Z; Wu J; Zhou X; Zeng F
    Arzneimittelforschung; 2012 Feb; 62(2):75-82. PubMed ID: 22344551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats.
    Gao W; Jusko WJ
    J Pharmacol Exp Ther; 2011 Mar; 336(3):881-90. PubMed ID: 21156817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Target-mediated pharmacokinetic/pharmacodynamic model based meta-analysis and dosing regimen optimization of a long-acting release formulation of exenatide in patients with type 2 diabetes mellitus.
    Li H; Xu J; Fan X
    J Pharmacol Sci; 2015 Feb; 127(2):170-80. PubMed ID: 25727954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology of the glucagon-like peptide-1 analog exenatide extended-release in healthy cats.
    Rudinsky AJ; Adin CA; Borin-Crivellenti S; Rajala-Schultz P; Hall MJ; Gilor C
    Domest Anim Endocrinol; 2015 Apr; 51():78-85. PubMed ID: 25594949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Mitiglinide Combined with Dapagliflozin in Streptozotocin-nicotinamide-induced Type 2 Diabetic Rats and in Zucker Fatty Rats.
    Akahane K; Inoue T; Yokoyama A; Yaguchi A; Ojima K; Kiguchi S; Maruyama K; Kobayashi M; Mori Y
    Drug Res (Stuttg); 2015 Aug; 65(8):416-21. PubMed ID: 25188606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exenatide can reduce glucose independent of islet hormones or gastric emptying.
    Ionut V; Zheng D; Stefanovski D; Bergman RN
    Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E269-77. PubMed ID: 18492781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exenatide Treatment Alone Improves β-Cell Function in a Canine Model of Pre-Diabetes.
    Ionut V; Woolcott OO; Mkrtchyan HJ; Stefanovski D; Kabir M; Iyer MS; Liu H; Castro AV; Wu Q; Broussard JL; Kolka CM; Asare-Bediako I; Bergman RN
    PLoS One; 2016; 11(7):e0158703. PubMed ID: 27398720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes.
    Molina Vega M; Muñoz-Garach A; Tinahones FJ
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):207-217. PubMed ID: 29260924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.